RASH
MCID: EXN002
MIFTS: 56

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Name: Exanthem 12 15
Exanthema 12 44
Rash 12 15
Rashes 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0050486
ICD10 33 R21
ICD9CM 35 782.1
MeSH 44 D005076
SNOMED-CT 68 1806006
UMLS 73 C0015230

Summaries for Exanthem

MedlinePlus : 43 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to drug reaction with eosinophilia and systemic symptoms and aseptic meningitis. An important gene associated with Exanthem is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Irinotecan and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia : 76 An exanthem or exanthema (from Greek ἐξάνθημα exánth�?ma, "a breaking out") is a widespread rash usually... more...

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 drug reaction with eosinophilia and systemic symptoms 30.5 CRP TNF
2 aseptic meningitis 30.4 IL1RN NLRP3 TNF
3 meningitis 30.2 CRP IL6 NLRP3 TLR9 TNF
4 viral infectious disease 30.2 IL2 IL6 TLR9 TNF
5 mouth disease 30.1 CRP IL6 TLR9 TNF
6 arthritis 30.0 IL1RN IL6 TNF TNFRSF1B
7 pneumonia 30.0 CRP IL6 TLR9 TNF
8 kawasaki disease 29.9 CRP IL6 TNF
9 human immunodeficiency virus infectious disease 29.9 IL2 IL6 TLR9 TNF
10 lyme disease 29.9 CRP IL6 TNF
11 gastroenteritis 29.9 CRP IL6 TNF
12 purpura 29.9 CRP IL6 TNF
13 graft-versus-host disease 29.8 IL2 IL6 TNF
14 acquired immunodeficiency syndrome 29.8 IL2 IL6 TNF
15 exanthema subitum 29.8 IL2 IL6 TNFRSF1B
16 lung disease 29.8 EGFR IL6 TLR9 TNF
17 pericarditis 29.7 CRP IL1RN IL6 TNF
18 brucellosis 29.6 CRP IL1RN IL2 IL6 TNF
19 myeloma, multiple 29.3 CRP HRAS IL2 IL6 KRAS TLR9
20 leukemia, acute myeloid 29.3 HRAS IL2 KRAS MAP2K7 MTOR TNF
21 psoriasis 29.0 AREG IL2 IL6 TLR9 TNF TNFRSF1B
22 bacterial exanthem 12.3
23 viral exanthem 12.3
24 severe cutaneous adverse reaction 11.4
25 hand, foot and mouth disease 11.4
26 contagious pustular dermatitis 11.1
27 progesterone-receptor negative breast cancer 10.3 EGFR ERBB2
28 breast scirrhous carcinoma 10.3 EGFR ERBB2
29 apocrine adenoma 10.3 HRAS KRAS
30 systemic onset juvenile idiopathic arthritis 10.3 IL1RN TNF
31 measles 10.3
32 hyperglobulinemic purpura 10.3 HSPG2 TRIM21
33 skin sarcoidosis 10.3 TNF TNFRSF1B
34 cold agglutinin disease 10.3 CRP IL6
35 colorectal adenocarcinoma 10.3 EGFR HRAS KRAS
36 subacute cutaneous lupus erythematosus 10.3 TNF TRIM21
37 differentiated thyroid carcinoma 10.3 EGFR HRAS KRAS
38 breast intraductal proliferative lesion 10.3 EGFR ERBB2
39 uterine carcinosarcoma 10.3 EGFR ERBB2 HRAS
40 endometrial adenocarcinoma 10.3 EGFR ERBB2 KRAS
41 colorectal adenoma 10.3 CRP HRAS KRAS
42 schnitzler syndrome 10.2 CRP IL1RN NLRP3
43 systemic scleroderma 10.2 CRP TLR9 TRIM21
44 carcinosarcoma 10.2 ERBB2 HRAS KRAS
45 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
46 leukomalacia 10.2 IL6 TNF
47 scorpion envenomation 10.2 IL6 TNF
48 arthropathy 10.2 CRP NLRP3 TNF
49 renal cell carcinoma, papillary, 1 10.2 ERBB2 HRAS MTOR
50 vulvar vestibulitis syndrome 10.2 IL1RN NLRP3 TNF

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.59 EGFR HRAS KRAS MTOR KALRN
2 Decreased viability GR00106-A-0 10.59 KRAS
3 Decreased viability GR00221-A-1 10.59 EGFR HRAS KRAS MAP2K7 MTOR
4 Decreased viability GR00221-A-2 10.59 HRAS KRAS
5 Decreased viability GR00221-A-3 10.59 HRAS
6 Decreased viability GR00221-A-4 10.59 EGFR MTOR
7 Decreased viability GR00301-A 10.59 KRAS KALRN
8 Decreased viability GR00342-S-1 10.59 MAP2K7 MTOR KALRN
9 Decreased viability GR00342-S-2 10.59 MTOR KALRN
10 Decreased viability GR00342-S-3 10.59 KALRN
11 Decreased viability GR00381-A-1 10.59 KRAS KALRN
12 Decreased viability GR00402-S-2 10.59 EGFR HRAS KRAS MAP2K7 MTOR KALRN
13 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 EGFR ERBB2 HRAS HSPG2 KALRN MTOR
14 Decreased cell migration GR00055-A-1 9.77 EGFR HRAS KALRN KRAS MTOR
15 Decreased viability with paclitaxel GR00179-A-1 9.7 EGFR MTOR ERBB2
16 Decreased viability with paclitaxel GR00179-A-2 9.7 MTOR
17 Decreased viability with paclitaxel GR00179-A-3 9.7 EGFR MTOR
18 Decreased substrate adherent cell growth GR00193-A-2 9.65 EGFR KALRN MAP2K7 MTOR
19 Decreased substrate adherent cell growth GR00193-A-3 9.65 MAP2K7
20 Reduced mammosphere formation GR00396-S 9.17 EGFR HRAS HSPG2 KRAS MTOR TLR9

MGI Mouse Phenotypes related to Exanthem:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.53 AREG CRP CTLA4 EGFR ERBB2 HRAS
2 cardiovascular system MP:0005385 10.48 AREG CRP CTLA4 EGFR ERBB2 HRAS
3 mortality/aging MP:0010768 10.45 AREG CTLA4 EGFR ERBB2 HRAS HSPG2
4 hematopoietic system MP:0005397 10.43 AREG CTLA4 EGFR HSPG2 IL1RN IL2
5 cellular MP:0005384 10.41 EGFR ERBB2 HSPG2 IL1RN IL2 IL6
6 growth/size/body region MP:0005378 10.41 AREG EGFR ERBB2 HRAS HSPG2 IL1RN
7 immune system MP:0005387 10.41 AREG CRP CTLA4 EGFR HSPG2 IL1RN
8 digestive/alimentary MP:0005381 10.4 AREG CTLA4 EGFR ERBB2 HRAS HSPG2
9 integument MP:0010771 10.4 AREG CTLA4 EGFR ERBB2 HRAS HSPG2
10 endocrine/exocrine gland MP:0005379 10.39 AREG CTLA4 EGFR ERBB2 HRAS IL2
11 behavior/neurological MP:0005386 10.35 ERBB2 HRAS HSPG2 IL2 IL6 KALRN
12 nervous system MP:0003631 10.21 EGFR ERBB2 HRAS HSPG2 IL6 KALRN
13 liver/biliary system MP:0005370 10.16 CTLA4 EGFR HSPG2 IL2 IL6 KRAS
14 craniofacial MP:0005382 10.14 EGFR ERBB2 HRAS HSPG2 KRAS TNF
15 muscle MP:0005369 10.13 EGFR ERBB2 HSPG2 IL6 KALRN KRAS
16 neoplasm MP:0002006 10.11 EGFR ERBB2 HRAS IL2 IL6 KRAS
17 normal MP:0002873 10.07 CTLA4 EGFR ERBB2 HRAS KALRN KRAS
18 reproductive system MP:0005389 10 AREG EGFR ERBB2 IL1RN IL2 IL6
19 renal/urinary system MP:0005367 9.97 EGFR HRAS IL6 KRAS MTOR NLRP3
20 no phenotypic analysis MP:0003012 9.95 EGFR HRAS IL2 KALRN KRAS MTOR
21 respiratory system MP:0005388 9.9 CTLA4 EGFR ERBB2 HRAS HSPG2 IL2
22 skeleton MP:0005390 9.73 CTLA4 EGFR ERBB2 HRAS HSPG2 IL1RN
23 vision/eye MP:0005391 9.28 AREG EGFR HSPG2 IL2 IL6 KRAS

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
3
Phytonadione Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 84-80-0 4812 5284607
4
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
5
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6
7
Zinc oxide Approved Phase 4,Phase 3,Not Applicable 1314-13-2
8
Vancomycin Approved Phase 4,Phase 3,Not Applicable 1404-90-6 14969 441141
9
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 55-56-1 2713 9552079
10
Mupirocin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 12650-69-0 446596
11
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-72-7 338
12
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2 56-12-2 119
13
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
14
Piperacillin Approved Phase 4,Not Applicable 66258-76-2 43672
15
Sulbactam Approved Phase 4,Phase 2 68373-14-8
16
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 58-14-0 4993
17
Azithromycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 83905-01-5 55185 447043
18
Sulfadoxine Approved, Investigational Phase 4,Phase 1,Phase 2 2447-57-6 17134
19
Ketorolac Approved Phase 4,Not Applicable 66635-83-4, 74103-06-3 3826
20
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
21
Travoprost Approved Phase 4 157283-68-6 5282226
22
Iron Approved Phase 4,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
23
Ferrous fumarate Approved Phase 4 141-01-5
24
Cefazolin Approved Phase 4,Phase 3,Not Applicable 25953-19-9 656510 33255
25
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
26
Ketotifen Approved Phase 4,Phase 3 34580-14-8, 34580-13-7 3827
27
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
28
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
29
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
30
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
31 Pinaverium Approved Phase 4 59995-65-2
32
Salmon Calcitonin Approved, Investigational Phase 4,Not Applicable 47931-85-1 16129616
33
Tazobactam Approved Phase 4 89786-04-9 123630
34
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
35
Cefuroxime Approved Phase 4,Phase 2,Not Applicable 55268-75-2 5361202 5479529
36
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
37
Ciprofloxacin Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
38
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
39
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
40
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
41
Nevirapine Approved Phase 4,Phase 3,Phase 1,Phase 2 129618-40-2 4463
42
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
43 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7681-49-4
44
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
45
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
46
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
47
Caffeine Approved Phase 4,Phase 1,Not Applicable 58-08-2 2519
48
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
49
Sorafenib Approved, Investigational Phase 4,Phase 2 284461-73-0 216239 406563
50
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 3200)
# Name Status NCT ID Phase Drugs
1 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
2 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
3 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
5 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
6 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
7 Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection Unknown status NCT02547103 Phase 4
8 Effectiveness and Economic Evaluation of Glass Ionomer Material Using as Dental Sealant Unknown status NCT03034837 Phase 4 resin sealant;ART sealant
9 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
10 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
11 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
12 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
13 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
14 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
15 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
16 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
17 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
18 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
19 The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection Unknown status NCT02307006 Phase 4 Ceftaroline;Cefazolin / Vancomycin
20 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
21 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Unknown status NCT02944461 Phase 4 Dapsone 7.5 % gel
22 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
23 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
24 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
25 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
26 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
27 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
28 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
29 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
30 Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash Completed NCT00219466 Phase 4
31 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
32 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
33 Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients Completed NCT01329731 Phase 4 elmex® gelée;negative control (placebo)
34 Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients Completed NCT02184299 Phase 4 Nevirapine;Prednisone
35 Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot Completed NCT02742285 Phase 4 Artemether + lumefantrine
36 Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study Completed NCT00723515 Phase 4 sodium fluoride;sodium fluoride calcium fluoride
37 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
38 Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients Completed NCT01768390 Phase 4
39 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
40 Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Completed NCT02131220 Phase 4 Prourokinase;Tirofiban;normal saline
41 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Completed NCT01149876 Phase 4 Tretinoin cream 0.05
42 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
43 Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity. Completed NCT01195194 Phase 4 PRE-TRANSPLANT (PRE=before)
44 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
45 Efficacy of Pentoxifylline on Chronic Kidney Disease Completed NCT00155246 Phase 4 pentoxifylline (drug)
46 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
47 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
48 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
49 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
50 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

41
Skin, Testes, Breast, Myeloid, Prostate, Lung, Kidney

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 494)
# Title Authors Year
1
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )
2018
2
Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )
2018
3
What's in a Rash? Viral Exanthem Versus CBRNE Exposure: Teleconsultation Support for Two Special Forces Soldiers With Diffuse Rash in an Austere Environment. ( 29889970 )
2018
4
Asymmetric periflexural exanthem: not a distinctive disease of childhood. ( 29582621 )
2018
5
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )
2018
6
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
7
Exanthem, Fieber und Arthralgien bei einer 19-jAohrigen Patientin. ( 29645383 )
2018
8
Eosinophilia, pruritic exanthema and digital necrosis. ( 28624075 )
2018
9
Infant with exanthema and fever. ( 27876188 )
2018
10
Immunohistochemical Demonstration of Parvovirus B19 Viral Protein 2 in Periflexural Exanthema in an Adult, Supporting Antibody-Dependent Enhancement as Means of Endothelial Uptake of the Virus. ( 28700372 )
2018
11
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. ( 29288229 )
2018
12
A 62-Year-Old Woman With Fever and Exanthema. ( 29521699 )
2018
13
Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. ( 29546073 )
2018
14
Overlap Between DRESS Syndrome and Exanthema Induced by Sulfadiazine in a Patient Treated With Sulfamethoxazole: Utility of the Lymphocyte Transformation Test for Identification of the Culprit Drug. ( 29661742 )
2018
15
Tacrolimus-induced symmetric drug-related intertriginous and flexural exanthema (SDRIFE). ( 29722025 )
2018
16
Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon? ( 29782303 )
2018
17
First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. ( 29808929 )
2018
18
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. ( 30062790 )
2018
19
Palmoplantar exanthema and liver dysfunction. ( 30102597 )
2018
20
Diffuse maculopapular exanthema and a positive lymphocyte transformation test reaction in response to clarithromycin. ( 30159155 )
2018
21
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. ( 30323078 )
2018
22
Unilateral laterothoracic exanthem. ( 28754336 )
2017
23
Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )
2017
24
TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )
2017
25
Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )
2017
26
Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )
2017
27
Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )
2017
28
Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )
2017
29
Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )
2017
30
IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )
2017
31
Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )
2017
32
Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )
2017
33
Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. ( 27373553 )
2017
34
Exanthema, fever and arthralgia in a pregnant woman. ( 26493355 )
2017
35
Fixed exanthema emerged following narrowband ultraviolet B irradiation. ( 27543011 )
2017
36
Occurrence of equine coital exanthema (ECE) in stallions in Japan and effectiveness of treatment with valacyclovir for ECE. ( 28123140 )
2017
37
Isolation of equine herpesvirus 3 (EHV-3) from equine coital exanthema of two stallions and sero-epidemiology of EHV-3 infection in Japan. ( 28132964 )
2017
38
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. ( 28217835 )
2017
39
Symmetrical drug-related intertriginous and flexural exanthema possibly due to thiamine disulfide. ( 28225167 )
2017
40
Main Characteristics of Zika Virus Exanthema in Guadeloupe. ( 28241170 )
2017
41
Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). ( 28514083 )
2017
42
Pustulobullöse Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). ( 28591434 )
2017
43
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient. ( 28677584 )
2017
44
Allergic Maculo-Papular Exanthema Due To Terbinafine. ( 28785353 )
2017
45
Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. ( 28954125 )
2017
46
Symmetric Drug-related Intertriginous and Flexural Exanthema due to Itraconazole: An Uncommon Side Effect of a Commonly Used Drug. ( 29204404 )
2017
47
Symmetrical Drug-related Intertriginous and Flexural Exanthema Induced by Doxycycline. ( 29340257 )
2017
48
Asymmetric periflexural/unilateral laterothoracic exanthem related to parvovirus B19 infection: An adult carrier of A9-globin thalassaemia gene mutation in Hong Kong. ( 29896828 )
2016
49
Eruptive Hypomelanosis in a Young Child as a "Paraviral Exanthem". ( 26646426 )
2016
50
Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )
2016

Variations for Exanthem

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 AREG EGFR ERBB2 HRAS IL2 IL6
2
Show member pathways
13.96 AREG EGFR ERBB2 HRAS HSPG2 IL2
3
Show member pathways
13.87 CRP CTLA4 EGFR ERBB2 HRAS IL1RN
4
Show member pathways
13.77 EGFR ERBB2 HRAS IL1RN IL2 IL6
5
Show member pathways
13.67 AREG CRP EGFR ERBB2 HRAS IL2
6
Show member pathways
13.61 AREG EGFR ERBB2 HRAS IL2 IL6
7
Show member pathways
13.43 EGFR ERBB2 HRAS IL1RN IL2 IL6
8
Show member pathways
13.41 AREG EGFR ERBB2 HRAS IL2 IL6
9
Show member pathways
13.41 AREG EGFR ERBB2 HRAS IL2 IL6
10
Show member pathways
13.37 AREG EGFR ERBB2 HRAS IL2 IL6
11
Show member pathways
13.36 AREG EGFR ERBB2 HRAS IL2 IL6
12
Show member pathways
13.26 AREG EGFR ERBB2 HRAS IL2 KRAS
13
Show member pathways
13.16 AREG EGFR HRAS HSPG2 IL2 IL6
14
Show member pathways
13.15 AREG EGFR HRAS IL2 IL6 KRAS
15
Show member pathways
13.11 EGFR HRAS HSPG2 IL6 KRAS MAP2K7
16
Show member pathways
13.1 IL2 IL6 MAP2K7 NLRP3 TLR9 TNF
17
Show member pathways
13.05 EGFR HRAS IL6 KRAS MAP2K7 MTOR
18
Show member pathways
12.99 AREG EGFR ERBB2 HRAS IL2 IL6
19
Show member pathways
12.98 CTLA4 HRAS IL2 IL6 TNF TNFRSF1B
20
Show member pathways
12.98 AREG EGFR ERBB2 HRAS KRAS MTOR
21
Show member pathways
12.98 EGFR ERBB2 HRAS IL6 KRAS MAP2K7
22 12.94 EGFR ERBB2 HRAS IL2 IL6 KRAS
23
Show member pathways
12.9 IL2 IL6 MAP2K7 NLRP3 TLR9 TNF
24
Show member pathways
12.88 HRAS IL2 IL6 KRAS MTOR TNF
25
Show member pathways
12.87 EGFR ERBB2 HRAS IL6 KRAS MAP2K7
26 12.86 AREG EGFR ERBB2 HRAS KRAS MAP2K7
27
Show member pathways
12.85 EGFR ERBB2 HRAS KRAS MTOR
28
Show member pathways
12.81 EGFR ERBB2 HRAS KRAS MTOR
29
Show member pathways
12.8 ERBB2 HRAS KRAS MAP2K7 MTOR
30
Show member pathways
12.8 AREG EGFR IL2 IL6 TLR9 TNF
31
Show member pathways
12.79 EGFR HRAS KRAS MAP2K7 TNF TNFRSF1B
32
Show member pathways
12.76 EGFR HRAS KRAS MAP2K7 MTOR
33
Show member pathways
12.72 HRAS IL2 MAP2K7 TNF TNFRSF1B
34
Show member pathways
12.7 HRAS MAP2K7 TLR9 TNF TNFRSF1B
35
Show member pathways
12.69 EGFR ERBB2 HRAS IL2 IL6 KRAS
36 12.68 CTLA4 IL1RN IL2 TLR9 TNF TNFRSF1B
37 12.62 EGFR ERBB2 HRAS KRAS MTOR
38
Show member pathways
12.61 AREG EGFR ERBB2 HRAS KRAS MAP2K7
39
Show member pathways
12.59 ERBB2 HRAS IL1RN KRAS MTOR
40
Show member pathways
12.54 EGFR ERBB2 HRAS IL2 KRAS MTOR
41
Show member pathways
12.54 EGFR ERBB2 HRAS KRAS MTOR TNF
42
Show member pathways
12.53 EGFR HRAS KRAS MAP2K7 TLR9
43 12.53 HRAS IL2 IL6 KRAS TNF
44
Show member pathways
12.52 EGFR HRAS IL2 IL6 KRAS MTOR
45
Show member pathways
12.5 AREG EGFR ERBB2 HRAS KRAS MAP2K7
46
Show member pathways
12.48 EGFR HRAS KRAS MTOR
47
Show member pathways
12.43 HRAS HSPG2 KRAS MTOR
48
Show member pathways
12.42 CRP IL2 IL6 TNF
49
Show member pathways
12.41 CTLA4 HRAS IL2 IL6 KRAS MAP2K7
50
Show member pathways
12.4 EGFR ERBB2 HRAS KRAS

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 AREG CRP EGFR HSPG2 IL1RN IL2
2 extracellular region GO:0005576 9.32 CRP EGFR HSPG2 IL1RN IL2 IL6
3 membrane raft GO:0045121 9.26 EGFR KRAS TNF TNFRSF1B

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 EGFR ERBB2 HRAS TNF
2 cellular response to lipopolysaccharide GO:0071222 9.93 IL1RN IL6 NLRP3 TNF TNFRSF1B
3 cytokine-mediated signaling pathway GO:0019221 9.93 IL1RN IL2 IL6 KRAS TNF TNFRSF1B
4 positive regulation of protein kinase B signaling GO:0051897 9.92 EGFR ERBB2 MTOR TNF
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.89 IL6 KRAS NLRP3 TLR9 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.88 CRP IL6 NLRP3 TNF
7 positive regulation of JNK cascade GO:0